Class / Patent application number | Description | Number of patent applications / Date published |
514475000 | The hetero ring is three-membered | 81 |
20090069418 | Compositions and Methods for the Treatment of Disorders Associated with Aberrant Vasodilation - Methods and compositions for the treatment of conditions associated with improper vasodilation are provided. | 03-12-2009 |
20090163587 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS - Ester prodrugs of phorbol compounds for the treatment of viral infections, neoplastic diseases, inflammatory reactions, and use as analgesics, wherein the phorbol compounds are derivatized with a -x-o-c(o)-R′ group linked to the 6-carbon of the phorbol residue. | 06-25-2009 |
20090176874 | TNP-470 POLYMER CONJUGATES AND USE THEREOF - The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa. | 07-09-2009 |
20090197949 | ANTITUMOR METHODS AND COMPOSITIONS COMPRISING SESQUITERPENE DERIVATIVES - The present invention relates to novel antitumor compositions, the use of sesquiterpene derivatives as antitumor agents and to methods of treatment thereof. More precisely, The present invention relates to an antitumor composition comprising a therapeutically effective quantity of at least one sesquiterpene derivative in association with a pharmaceutically acceptable carrier. | 08-06-2009 |
20090203775 | Novel compound and a novel microorganism for producing the novel compound - The present invention relates to a novel compound represented as by formula (I). The present invention also provides a novel strain named as | 08-13-2009 |
20090270498 | Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders - Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed. | 10-29-2009 |
20090270499 | Process for Synthesizing Atazanavir - This invention relates to a process for synthesizing Atazanvir, including novel intermediates and novel steps to various intermediates along the synthetic pathway. | 10-29-2009 |
20090275652 | BIOFILM FORMATION INHIBITOR COMPOSITION - A drug and a composition for inhibiting biofilm formation are provided. A biofilm formation inhibitor composition containing the following component (A): (A) at least one or more selected from compounds represented by Formula (1) to Formula (4): wherein R | 11-05-2009 |
20090326058 | CaSR Antagonist - A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: | 12-31-2009 |
20100016425 | METHODS OF TREATING AN OVERWEIGHT OR OBESE SUBJECT - The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions. | 01-21-2010 |
20100056623 | FUMAGILLOL DERIVATIVES OR METHOD FOR PREPARATION OF FUMAGILLOL DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The present invention relates to a fumagillol derivative, pharmaceutically acceptable salts thereof and a method for preparing the same. The compounds of the present invention can be prepared through acylation, hydrolysis and alkylation. The compound of the present invention can be prepared in the form of a pharmaceutically acceptable salt or inclusion compound. The present invention provides fumagillol derivatives having the following characteristics: increased inhibiting effect on angiogenesis, low toxicity, excellent solubility and chemical stability as compared to conventional angiogenesis inhibitors. The compounds of the present invention can be used as an anti-cancer medicine, inhibitor of cancer metastasis, or the therapeutic agent for treating rheumatic arthritis, psoriasis, diabetic retinitis or obesity. | 03-04-2010 |
20100056624 | ANIMAL MODEL FOR PERIMENOPAUSE AND MENOPAUSE AND METHODS OF INDUCING OVARIAN FAILURE - The present invention relates to an animal model for human perimenopause and menopause. Also provided by the present invention are methods of making the animal model and methods of screening using the model. Also provided are methods of inducing ovarian failure in animals such as pets and wildlife. | 03-04-2010 |
20100093847 | ANTI-OBESITY ACTIVE AGENT AND ANTI-OBESITY METHOD - [Problem] Fucoxanthin extracted from wakame seaweed ( | 04-15-2010 |
20100152286 | Method for Producing Fucoxanthin - The present invention provides a method for producing fucoxanthin extract, said method comprising: performing absorption of the fucoxanthin extract by using absorbent and then performing elution to remove heavy metals and arsenic salt contained in the fucoxanthin extract, wherein the absorbent is selected from a group having macroporous resin, polyamide, activated carbon, alumina and a combination thereof. The method for producing fucoxanthin extract according to the present invention, the content of heave metal in the fucoxanthin extract can be reduced, while the content of fucoxanthin in the fucoxanthin extract can increase. In addition, the present invention also provides a fucoxanthin extract obtained by the above method, as well as fucoxanthin products containing the fucoxanthin extract. | 06-17-2010 |
20100184853 | TERPENES WITH ANTIFUNGAL ACTIVITY AGAINST MALASSEZIA YEASTS - The present invention relates to the use of some terpenes, for example chlovalicin, ovalicin or fumagillin, as antifungal against | 07-22-2010 |
20100190848 | Cysteine-protease inhibitors - Substantially pure diastereoisomeric compounds of formula Ia, alternatively Ib, or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, including hydrates, wherein PG is a protective group; R | 07-29-2010 |
20100190849 | Novel Clerodanes and Methods for Repelling Arthropods - A method for repelling arthropods involving treating a subject or an object with an arthropod repelling composition containing an arthropod repelling effective amount of at least one clerodane of the formula | 07-29-2010 |
20100197782 | THERAPEUTIC AGENT FOR VIRUS-ASSOCIATED MALIGNANCY - A therapeutic agent comprising fucoxanthin or fucoxanthinol as an active component is disclosed. The therapeutic agent is effective and high clinical utility for medical treatment and prevention of virus-associated malignancy such as adult T-cell leukemia and Burkitt lymphoma. | 08-05-2010 |
20100216875 | METHODS OF TREATING ALZHEIMER'S DISEASE - The invention is directed to a method of treating Alzheimer's disease. The method comprises administering a cysteine protease inhibitor to a patient and thereby affecting the disease. In a preferred method, the cysteine protease inhibitor is a cathepsin B inhibitor. A preferred method causes a reversal in the progression of the Alzheimer's disease, especially an improvement in cognitive deficit. A preferred method also causes a reduction in Aβ. The method includes using a reversible or irreversible cysteine protease inhibitor or a combination thereof. | 08-26-2010 |
20100222426 | Anti-Bacterial Agents - The invention relates to novel acylphloroglucinols which have strong growth inhibitory effects on multi-drug resistant strains of bacteria, particularly MRSA. Typically the compounds have a terpene substituent, or a terpene-derived substituent. Methods of isolating the compounds from natural sources, and synthetic methods for forming the compounds are also provided. | 09-02-2010 |
20100317733 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS - It has now been discovered that inhibitors of soluble epoxide hydrolase (“sEH”) are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosantrienoic acid (“EET”) in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced numbers of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA. | 12-16-2010 |
20100324133 | Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders - The present invention provides certain diepoxide carbocyclic compounds wherein at least one carbocyclic ring carbon includes two non-epoxide substituents, and pharmaceutical compositions containing the same, for the treatment or prophylaxis of inflammatory, autoimmune and hyper- or abnormally proliferative diseases and disorders. | 12-23-2010 |
20110015262 | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition - Methods and compositions for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using combination of compounds, or a bifunctional compound, that inhibits both fatty acid metabolism and glycolysis. In particular, the invention combines or links a glycolysis inhibitor that is, or that is derived from, hypoglycin A (also referred to as hypoglycine A) and a fatty acid metabolism inhibitor. Preferably, the invention provides bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a hypoglycin A derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of hypoglycin A. | 01-20-2011 |
20110021627 | NITRILE COMPOUND AND ITS USE FOR CONTROL OF ARTHROPOD PEST - There is provided a nitrile compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein m represents in integer of 0 to 4; n represents an integer of 1 to 4; q represents an integer of 0 to 4; Q represents a C1-C4 fluoroalkyl group; Z represents an optionally substituted C2-C6 alkynyl group or a ═N—OR | 01-27-2011 |
20110034550 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same - The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis. | 02-10-2011 |
20110105603 | COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES - In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin. In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g., AD, VD, CDS. The invention also provides alternative dosage forms and formulations for AB-007 and loxistatin, and for compounds of this invention, which can be used e.g., to treat AD, VD and CDS, in humans and in non-human animals. | 05-05-2011 |
20110118347 | TREATMENT Of RINGWORM - A compound of the formula CH | 05-19-2011 |
20110136901 | Derivatives of 4-Nerolidylcatechol, Pharmaceutical Compositions Comprising them and Process for Producing The Same - The present invention discloses 4-nerolidylcatechol and its derivatives isolated from South American/Amazon plants ( | 06-09-2011 |
20110136902 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES - There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R | 06-09-2011 |
20110144200 | COMBINATION OF CAROTENOIDS AND EPI-LUTEIN - The invention describes the preparation and use of carotenoid and epi-lutein compositions to treat various ocular diseases. | 06-16-2011 |
20110178172 | Inhibitors of Carnitin-Palmitoyl-Tranferase-1 for the Treatment and prevention of disorders caused by delipidation of neural tissue - Carnitin-Palmitoyl-Transferase-1 (CPT-1) inhibitor for use in treating and/or preventing disorders caused by delipidation of neural tissue. | 07-21-2011 |
20110190389 | OXYLIPINS FROM LONG CHAIN POLYUNSATURATED FATTY ACIDS AND METHODS OF MAKING AND USING THE SAME - Disclosed are novel oxylipins, referred to herein as docosanoids and eicosanoids, that are derived from C22 polyunsaturated fatty acids and from C20 polyunsaturated fatty acids, respectively, and methods of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6), docosatrienoic acid (C22:3n-3) (DTrAn-3), docosadienoic acid (C22:2n-6) (DDAn-6), eicosatrienoic acid (C20:3n-3) (ETrAn-3) eicosapentaenoic acid and arachidonic acid as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUF A)-rich oils and compositions that contain enhanced and effective amounts of LCPUF A-derived oxylipins, and particularly, docosanoids. | 08-04-2011 |
20110269831 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS - The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher. | 11-03-2011 |
20110288168 | HISTONE DEACETYLASE INHIBITORS - Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. | 11-24-2011 |
20120004299 | AZEOTROPE-LIKE COMPOSITIONS OF CIS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE - This invention relates to azeotrope-like compositions, methods and systems having utility in numerous applications, and in particular, uses for azeotrope-like compositions comprising effective amounts of the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm), which has the following structure: | 01-05-2012 |
20120046357 | Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) - The invention relates to compounds of formula (1) and formula (2), | 02-23-2012 |
20120088827 | Oxabicyclo[4.1.0]Hept-B-en-S-yl Carbamoyl Derivatives Inhibiting The Nuclear Factor-Kappa (B) - (NF-KB) - The invention relates to compounds of formula (I), formula (II), formula (III) and formula (IV), | 04-12-2012 |
20120122972 | NOVEL EICOSANOID DERIVATIVES - The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias. | 05-17-2012 |
20120129924 | USES OF SESQUITERPENE DERIVATIVES - The present invention relates to a pharmaceutical composition for preventing or treating hyperlipidemia, fatty liver, diabetes and obesity comprising a sesquiterpene derivative as an active ingredient. The sesquiterpene derivatives of the present invention leads to decrease in body fat weight, visceral fat weight and total cholesterol levels, triglyceride of plasma and liver tissue, blood glucose and blood insulin levels in a fast state, finally exhibiting efficacies on prevention or treatment of hyperlipidemia, fatty liver, diabetes and obesity. | 05-24-2012 |
20120149768 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. | 06-14-2012 |
20120309824 | AZEOTROPIC AND AZEOTROPE-LIKE COMPOSITIONS OF E-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE AND ETHYLENE OXIDE AND USES THEREOF - Azeotropic or azeotrope-like compositions are disclosed. The azeotropic or azeotrope-like compositions are mixtures of E-1,1,1,4,4,4-hexafluoro-2-butene and ethylene oxide. Also disclosed are double azeotropic compositions of E-1,1,1,4,4,4-hexafluoro-2-butene and ethylene oxide. Also disclosed is a process of preparing a thermoplastic or thermoset foam by using such azeotropic or azeotrope-like compositions as blowing agents. Also disclosed is a process of producing refrigeration by using such azeotropic or azeotrope-like compositions. Also disclosed is a process of using such azeotropic or azeotrope-like compositions as solvents. Also disclosed is a process of producing an aerosol product by using such azeotropic or azeotrope-like compositions. Also disclosed is a process of using such azeotropic or azeotrope-like compositions as heat transfer media. Also disclosed is a process of extinguishing or suppressing a fire by using such azeotropic or azeotrope-like compositions. Also disclosed is a process of using such azeotropic or azeotrope-like compositions as dielectrics. Also disclosed is a method for sterilizing an article by using such azeotropic or azeotrope-like compositions. | 12-06-2012 |
20120316233 | Crystalline Solids of a METAP-2 Inhibitor and Methods of Making and Using Same - The disclosure is in part directed to crystalline forms of 6-O-(4- dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof. | 12-13-2012 |
20120322867 | Methods of Treating an Overweight or Obese Subject - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions. In certain embodiments, the invention provides a method of treating an overweight or obese subject including administering a MetAP2 inhibitor in which the amount administered does not substantially modulate angiogenesis. | 12-20-2012 |
20130018094 | Prophylactic or Therapeutic Agent For Gum Disease or Apical PeriodontitisAANM Kawashima; NobuyukiAACI TokyoAACO JPAAGP Kawashima; Nobuyuki Tokyo JPAANM Suzuki; NoriyukiAACI TokyoAACO JPAAGP Suzuki; Noriyuki Tokyo JP - Monosodium (2S,3S)-3-[[(1S)-1-isobutozymethyl-3-methylbutyl]-carbamoyl]oxirane-2-carboxylate represented by the following formula is used as a prophylactic or therapeutic agent for periodontal diseases including gum disease and apical periodontitis. | 01-17-2013 |
20130018095 | Fumigillol Type Compounds and Methods of Making and Using Same - The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided. | 01-17-2013 |
20130172407 | Inhibition of Cancer Cell Proliferation Using Oleoylethanolamide - A pharmaceutical composition including oleoylethanolamide (OEA) is administered to inhibit tumor/cancer cell proliferation. The pharmaceutically composition may additionally include vitamin A, carotenoids, ω-3 polyunsaturated fatty acid, ω-6 polyunsaturated fatty acid and/or conjugated linolenic acid. The tumor/cancer may be colorectal cancer, lung adenocarcinoma, breast cancer, hepatoma, oral cancer and/or stomach adenocarcinoma. | 07-04-2013 |
20130197078 | Crystalline Solids of a METAP-2 Inhibitor and Methods of Making and Using Same - The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof. | 08-01-2013 |
20130225676 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT - The present invention concerns an antiviral composition comprising the following components: R-(−)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (−) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and ( | 08-29-2013 |
20130274327 | NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID - The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations. | 10-17-2013 |
20130289107 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL - The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol. | 10-31-2013 |
20130345302 | HONOKIOL ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers. | 12-26-2013 |
20140011870 | Methods of Treating Obesity Using an Effective Dose of a METAP-2 Inhibitor - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using effective of amounts of a MetAP-2 inhibitor. | 01-09-2014 |
20140045934 | Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g., a MetAP-2 inhibitor. | 02-13-2014 |
20140045935 | Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor. | 02-13-2014 |
20140051752 | Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol - The invention generally relates to methods of treating an overweight or obese subject, and treating overweight- or obesity-related conditions using non-daily administration of e.g, a MetAP-2 inhibitor. | 02-20-2014 |
20140057979 | Expression Modulator For Clock Gene - The present invention provides substances that can be used in a broad range of applications and effectively regulate clock gene expression. | 02-27-2014 |
20140073691 | Methods and composition for Treating Thyroid Hormone Related Disorders - The invention generally relates to methods of improving thyroid hormone sensitivity or treating a thyroid hormone resistance related disorder in a patient in need thereof, comprising administering a pharmaceutically effective amount of a MetAP-2 inhibitor. Such methods may include administering a MetAP-2 inhibitor at a dose that does not substantially modulate angiogenesis. | 03-13-2014 |
20140155479 | TIGLIEN-3-ONE DERIVATIVES - The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment. | 06-05-2014 |
20140256805 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS - The present disclosure is generally directed to neuroactive substituted cyclopenta[b]phenanthrenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 09-11-2014 |
20140275241 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS - The present disclosure is generally directed to neuroactive substituted cyclopent[a]anthracenes as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 09-18-2014 |
20140336251 | METHODS OF TREATING AGE RELATED DISORDERS - The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor. | 11-13-2014 |
20150018413 | Crystalline Solids of a METAP-2 Inhibitor and Methods of Making and Using Same - The disclosure is in part directed to crystalline forms of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol and variants thereof. | 01-15-2015 |
20150045427 | Oxaspiro[2.5]Octane Derivatives and Analogs - The invention provides oxaspiro[2.5]octane derivatives and analogs, methods for preparation thereof, intermediates thereto, pharmaceutical compositions, and uses thereof in the treatment of various disorders and conditions, such as overweight and obesity. | 02-12-2015 |
20150065568 | METHOD FOR PRODUCING COMPOSITION CONTAINING FUCOXANTHIN - A method for producing a composition containing fucoxanthin includes a first step of adding a water-soluble solvent containing 0 to 80% by weight of water to seaweed to obtain a seaweed component extract, and then adding water and/or a water-soluble solvent to the seaweed component extract in such a manner that the concentration of the water-soluble solvent is 20 to 45% by weight and also adding a diluent thereto to obtain a diluent-containing extract, and a second step of stirring the diluent-containing extract, and then collecting a substance aggregating into the diluent-containing extract as a composition containing fucoxanthin by separation. | 03-05-2015 |
20150099803 | VETERINARY USE OF DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, AND DIBROMODULCITOL TO TREAT MALIGNANCIES - The present invention is directed to methods for treatment of malignancies in companion animals employing dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol, as well as analogs and derivatives thereof, in addition to a method to improve the efficacy and/or reduce the side effects of the administration of a therapeutic agent selected from the group consisting of dianhydrogalactitol, a derivative of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative of dibromodulcitol to a veterinary subject, the method comprising the steps of: (1 (identifying at least one factor or parameter associated with the efficacy and/or occurrence of side effects of the administration of the therapeutic agent to the veterinary subject; and (2) modifying the factor or parameter to improve the efficacy and/or reduce the side effects of the administration of the therapeutic agent to the veterinary subject. | 04-09-2015 |
20150111963 | FUMIGILLOL TYPE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided. | 04-23-2015 |
20150111964 | POLYMORPHIC SALT OF A METAP-2 INHIBITOR AND METHODS OF MAKING AND USING SAME - The disclosure is in part directed to crystalline forms of an oxalate salt of 6-O-(4-dimethylaminoethoxy)cinnamoyl fumagillol. | 04-23-2015 |
20150119460 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS - The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof. | 04-30-2015 |
20150315162 | Process for producing fucoxanthinol extract and methods of use - A process for obtaining a purified fucoxanthinol extract from an Echinozoa tissue or organ is disclosed, as well as methods of using said extract. Compositions comprising the extract, and their uses, are also described. Uses of the purified extract include methods for making medicaments or treatments for conditions such as, but not limited to, obesity, cancer, oxidative stress, diabetes, neurodegenerative disorders, and high blood pressure. | 11-05-2015 |
20150329511 | METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL - The present invention provides an efficient method of synthesizing and purifying dianhydrohexitols such as dianhydrogalactitol. In general, as applied to dianhydrogalactitol, the method comprises: (1) reacting dulcitol with a concentrated solution of hydrobromic acid at a temperature of about 80° C. to produce dibromogalactitol; (2) reacting the dibromogalactitol with potassium carbonate in t-butanol to produce dianhydrogalactitol; and (3) purifying the dianhydrogalactitol using a slurry of ethyl ether to produce purified dianhydrogalactitol. Another method produces dianhydrogalactitol from dulcitol; this method comprises: (1) reacting dulcitol with a reactant to convert the 1,6-hydroxy groups of dulcitol to an effective leaving group to generate an intermediate; and (2) reacting the intermediate with an inorganic weak base to produce dianhydrogalactitol through an intramolecular S | 11-19-2015 |
20160008315 | NEURONAL CIRCUIT-DEPENDENT NEUROPROTECTION BY INTERACTION BETWEEN NICOTINIC RECEPTORS | 01-14-2016 |
20160038453 | METHODS OF TREATING RENAL DISEASE AND OTHER DISORDERS - The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor. | 02-11-2016 |
20160060236 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. | 03-03-2016 |
20160068499 | METHODS AND COMPOSITIONS FOR WOUND HEALING - The present invention relates to epoxy-tigliane compounds and their use in promoting wound healing. In particular embodiments, the epoxy-tigliane compounds are epoxy-tigliaen-3-one compounds. Methods of inducing or promoting wound healing as well as methods of reducing scarring and improving cosmetic outcomes upon healing of a wound are described. Compounds and compositions for use in wound healing are also described. | 03-10-2016 |
20160102067 | OXIRAN AMINES - Disclosed herein are oxiran amines useful for the treatment of a variety of diseases. The oxiran amines are useful in the manufacture of pharmaceutical compositions. The pharmaceutical composition may be used for the treatment or prevention of a disease caused by a virus having a lipid membrane or the pharmaceutical composition may be used for diseases requiring cell proliferation or immune-regulation. | 04-14-2016 |
20160106703 | FUMAGILLOL TYPE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The disclosure provides a fumagillol type compound and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided. | 04-21-2016 |
20160115112 | NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS - The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof. Resolution of inflammation is now held to be an active process where autacoids promote homeostasis. Using functional-metabololipidomics and in vivo systems, endogenous n-3 docosapentaenoic (DPA) acid is converted during inflammation-resolution in mice and by human leukocytes to novel n-3 products congenerous to D-series resolvins (Rv), protectins (PD) and maresins (MaR), termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include 7,8,17-trihydroxy-9,11,13,15E,19Zdocosapentaenoic acid (RvD1n_3 DPA), 7,14-dihydroxy-8,10,12,16Z,19Z-docosapentaenoic acid (MaR1n_3 DPA) and related bioactive products. | 04-28-2016 |
20160158187 | TIGLIEN-3-ONE DERIVATIVES - The present invention relates to tiglien-3-one compounds and their use in methods of treating or preventing protozoal infections, bacterial infections, parasitic infections and cell proliferative disorders. The tiglien-3-one compounds are also used in methods of controlling pests in humans, animals, plants and the environment. | 06-09-2016 |
20160168087 | SULFOPEROXYCARBOXYLIC ACIDS, THEIR PREPARATION AND METHODS OF USE AS BLEACHING AND ANTIMICORBIAL | 06-16-2016 |
20170233356 | NEUROACTIVE SUBSTITUTED CYCLOPENT[a]ANTHRACENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | 08-17-2017 |
20190142782 | INHIBITORS OF GLUCOSYLCERAMIDE DEGRADATION IN THE TREATMENT OF DISEASES OF THE MOTOR UNITS | 05-16-2019 |